Welcome to our dedicated page for Briacell Therapeutics SEC filings (Ticker: BCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BriaCell Therapeutics Corp. filings document a British Columbia clinical-stage biotechnology issuer with Nasdaq-listed common shares and warrant securities. The company's Form 8-K reports cover material events, Regulation FD disclosures, public-offering unit and warrant terms, capital-structure changes, and clinical or regulatory disclosures tied to its oncology immunotherapy programs.
Proxy and meeting filings disclose shareholder voting matters, director elections, auditor appointment, audited financial statements and the omnibus equity incentive plan. Other filings include BriaPro Therapeutics Corp. interim financial statements and management discussion furnished through BriaCell, as well as exchange records concerning removal of a warrant class from listing and registration.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerated cancer immunotherapy development. For the nine months ended April 30, 2026, the company lost $22.8 million, up from $18.4 million a year earlier, driven mainly by higher research, development, and clinical trial expenses of $18.7 million versus $14.2 million.
Cash, cash equivalents, and short-term investments totaled $22.8 million, with cash of $6.9 million and positive working capital of $21.8 million. However, a cumulative deficit of $134.3 million and operating cash outflows of $22.7 million over nine months led management to state that substantial doubt exists about BriaCell’s ability to continue as a going concern without additional financing.
Clinically, BriaCell advanced its Bria-IMT™ pivotal Phase 3 study in metastatic breast cancer under FDA Fast Track Designation, reporting extended survival and favorable safety signals, and broadened its pipeline with Bria-OTS™, Bria-OTS+™, and Bria-PROS+™ including new FDA clearance to begin a Phase 1/2a study for Bria-BRES+™.
BriaCell Therapeutics Corp. entered a Placement Agency Agreement with ThinkEquity for a best efforts equity offering of 1,449,300 common shares at $3.25 per share. The offering generated gross proceeds of about $4.71 million before fees and expenses.
The company plans to use the net proceeds for working capital, general corporate purposes, and advancing its business objectives. The shares were issued under an effective shelf registration statement on Form S-3. As compensation, BriaCell paid a cash fee of 7.5% of gross proceeds and issued Placement Agent Warrants to buy 72,465 common shares at an exercise price of $4.0625 per share, exercisable immediately and expiring five years after the agreement date.
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at an offering price of $3.25 per share pursuant to this prospectus supplement.
The placement agent for the offering is ThinkEquity LLC. Gross proceeds at the stated price are $4,710,225, with placement agent commissions of $353,267 (7.5%) and estimated net proceeds to the company of approximately $3.94 million. Closing of the offering is expected on or about June 2, 2026. The prospectus states common shares outstanding following the offering will be 8,699,787, and lists related equity instruments (warrants, options, RSUs, PSUs) with explicit counts and exercise/ conversion prices.
BriaCell Therapeutics Corp. is furnishing unaudited interim results for its subsidiary BriaPro Therapeutics and outlining a new oncology licensing deal. For the six months ended January 31, 2026, BriaPro recorded a net loss of $472,231, driven mainly by research and development spending of $433,307. The company has negative working capital of $1,638,799 and a cumulative deficit of $1,652,656, and the statements highlight material uncertainty about its ability to continue as a going concern, with operations funded by BriaCell.
On February 18, 2026, BriaPro agreed to acquire an exclusive worldwide license to develop and commercialize Soluble CD80 (sCD80) for cancer from BriaCell, along with related assets. As consideration and in connection with a $3,000,000 BriaCell credit facility, BriaPro will issue 23,972,589 common shares valued at approximately C$1.18 million, increasing BriaCell’s stake to about 78%. BriaPro will owe a 2% royalty on sCD80 sales to the University of Maryland, Baltimore County. Disinterested shareholders approved the transaction on March 5, 2026, and it closed on March 30, 2026.
BriaCell Therapeutics Corp. reported a larger net loss as it accelerates late-stage cancer trials. For the three months ended January 31, 2026, net loss was $7.3M versus $6.3M a year earlier, driven mainly by higher research and development spending.
Research, development, and clinical trial expenses for the half-year rose to $12.7M from $9.4M, reflecting intensive investment in the pivotal Phase 3 Bria‑IMT™ metastatic breast cancer study and the Bria‑OTS™ Phase 1/2a program. General and administrative costs were relatively stable at $3.1M for the six-month period.
The company strengthened its balance sheet, ending January 31, 2026 with cash and cash equivalents of $29.9M and positive working capital of $29.0M, helped by $27.9M in net equity financing during the half-year and a public offering of approximately $30.0M in gross proceeds. However, accumulated deficit reached $127.2M, and management states that uncertainty around securing future financing raises substantial doubt about BriaCell’s ability to continue as a going concern.
BriaCell Therapeutics Corp. held its Annual General and Special Meeting of Shareholders on March 5, 2026. Shareholders owning 3,502,695 common shares were present in person or by proxy, out of 7,250,487 common shares issued and outstanding as of the January 26, 2026 record date.
Shareholders ratified the appointment of MNP LLP as auditors, with 3,431,761 votes for and 70,934 withheld. Six directors were elected, including Dr. Jane Gross, Mr. Jamieson Bondarenko, Dr. William V. Williams, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin Schmieg.
Shareholders also re-approved the Company’s Omnibus Equity Incentive Plan, with 1,524,081 votes for, 362,949 against, and 1,615,665 broker non-votes, maintaining the Company’s existing framework for equity-based compensation.
BriaCell Therapeutics Corp. filed a Form 25 notifying removal of its Warrant class from listing and registration on the Nasdaq Stock Market LLC.
Nasdaq certified compliance with 17 CFR 240.12d2-2 procedures to strike the class and the filing states the issuer complied with the Exchange's voluntary withdrawal requirements. The notice is signed by Tara Petta, Director.
BriaCell Therapeutics Corp. has entered an asset purchase agreement with its majority‑owned subsidiary BriaPro Therapeutics Corp., transferring BriaCell’s exclusive license to develop and commercialize Soluble CD80 for cancer and related assets to BriaPro. As consideration, BriaPro will issue 23,972,589 BriaPro common shares, raising BriaCell’s ownership in BriaPro to about 78% after the transaction. BriaCell will also make available up to $3.0 million to BriaPro through a credit facility to fund research and development, with each drawdown subject to BriaCell’s approval. The deal is expected to close on or around March 12, 2026, subject to approval by disinterested BriaPro shareholders and receipt of an independent third‑party valuation confirming fair market value.
BriaCell Therapeutics Corp. has called its 2026 annual general and special meeting for March 5, 2026 in Toronto. Shareholders of record on January 26, 2026, representing 7,250,487 common shares, can vote in person or by proxy.
Investors will vote on appointing MNP LLP as auditor, electing six directors, and re-approving BriaCell’s rolling omnibus equity incentive plan, which allows equity awards up to 15% of shares outstanding, with additional caps for insiders and non-employee directors. The Board unanimously recommends voting “FOR” all three proposals.
BriaCell Therapeutics Corp. (BCTX) received a Schedule 13G filing from a group of Citadel-affiliated entities and Kenneth Griffin, disclosing a sizable passive stake in the company’s common shares.
The group reports beneficial ownership of 717,198 Shares, which represents 9.99% of BriaCell’s outstanding common shares. Within this, Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC may each be deemed to beneficially own 716,699 Shares (9.98% of the class), while Citadel Securities LLC and related entities may be deemed to beneficially own 499 Shares (0.0% of the class).
The reported percentages are based on 7,179,163 Shares outstanding, including 6,211,436 Shares outstanding as of January 15, 2026, 657,096 Shares issued upon voluntary warrant exercises by Citadel affiliates, and 310,631 Shares issuable upon conversion of warrants that are subject to a 9.99% beneficial ownership limitation.